Product/Composition:- | Cabazitaxel |
---|---|
Strength:- | 60 mg/1.5 mL |
Form:- | Injection |
Reference Brands:- | Jevtana®(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Cabazitaxel is an oncology drug used for advanced prostate cancer (mCRPC). Available as a 60 mg/1.5 mL injection in the US and EU under the brand Jevtana®.
Cabazitaxel, a next-generation taxane chemotherapy agent, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), especially in patients previously treated with docetaxel. Marketed under the brand Jevtana® in the US and EU, it is available as a 60 mg/1.5 mL injectable concentrate, requiring dilution before intravenous infusion. Cabazitaxel inhibits microtubule depolymerization, disrupting cancer cell mitosis. Manufactured under strict GMP standards, Cabazitaxel is a key product for B2B pharma partners focused on oncology and urology segments. It presents reliable commercial opportunities in highly regulated markets across Europe and North America.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications